SHANGHAI JUNSHI BIOSCIENCES CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.74 HKD | +4.88% |
|
+16.23% | -44.75% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,711 | 64,649 | 56,686 | 57,119 | 35,947 | 23,066 | - | - |
| Enterprise Value (EV) 1 | 18,402 | 62,115 | 53,714 | 52,363 | 33,930 | 20,466 | 21,397 | 21,944 |
| P/E ratio | -24.9 x | -23.4 x | -59.1 x | - | - | -5.72 x | -9.71 x | -15.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 24.1 x | 40.5 x | 14.1 x | 39.3 x | 23.9 x | 12.6 x | 7.26 x | 6.37 x |
| EV / Revenue | 23.7 x | 38.9 x | 13.3 x | 36 x | 22.6 x | 11.2 x | 6.74 x | 6.06 x |
| EV / EBITDA | -23.5 x | -41.7 x | -127 x | -21.7 x | -15.7 x | -11.2 x | -19.1 x | -21.6 x |
| EV / FCF | -9.3 x | -30.5 x | -38 x | -24.1 x | -12 x | -8.32 x | -21.7 x | -14.4 x |
| FCF Yield | -10.8% | -3.28% | -2.63% | -4.14% | -8.35% | -12% | -4.6% | -6.93% |
| Price to Book | 6.26 x | 7.14 x | 5.17 x | - | - | 1.35 x | 1.61 x | 1.64 x |
| Nbr of stocks (in thousands) | 784,147 | 872,496 | 910,757 | 982,872 | 985,011 | 984,908 | - | - |
| Reference price 2 | 23.86 | 47.81 | 47.26 | 42.83 | 17.67 | 9.942 | 9.942 | 9.942 |
| Announcement Date | 3/2/20 | 2/26/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 775.1 | 1,595 | 4,025 | 1,453 | 1,503 | 1,834 | 3,176 | 3,620 |
| EBITDA 1 | -783.5 | -1,490 | -422 | -2,417 | -2,168 | -1,823 | -1,122 | -1,015 |
| EBIT 1 | -747.3 | -1,636 | -558.3 | -2,666 | -2,457 | -1,851 | -1,111 | -394.1 |
| Operating Margin | -96.41% | -102.59% | -13.87% | -183.41% | -163.55% | -100.91% | -34.98% | -10.89% |
| Earnings before Tax (EBT) 1 | -763.1 | -1,672 | -595 | -2,677 | -2,492 | -1,967 | -883 | -433 |
| Net income 1 | -747.4 | -1,669 | -720.9 | -2,388 | -2,283 | -1,719 | -801.5 | -499.5 |
| Net margin | -96.43% | -104.62% | -17.91% | -164.3% | -151.97% | -93.71% | -25.24% | -13.8% |
| EPS 2 | -0.9600 | -2.040 | -0.8000 | - | - | -1.737 | -1.024 | -0.6399 |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,833 | -2,460 | -984.5 | -461.5 |
| FCF margin | -255.28% | -127.71% | -35.14% | -149.31% | -188.58% | -134.13% | -31% | -12.75% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/2/20 | 2/26/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 309 | 2,534 | 2,972 | 4,756 | 2,017 | 2,600 | 1,669 | 1,123 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,833 | -2,460 | -985 | -462 |
| ROE (net income / shareholders' equity) | -23.6% | -37.7% | -10.4% | -32.7% | -27.3% | -25.8% | -12.8% | -6.78% |
| ROA (Net income/ Total Assets) | -17.1% | -26.8% | -9.24% | - | -18.8% | -17.9% | -9.71% | -4.53% |
| Assets 1 | 4,360 | 6,228 | 7,802 | - | 12,138 | 9,617 | 8,256 | 11,039 |
| Book Value Per Share 2 | 3.810 | 6.690 | 9.150 | - | - | 7.390 | 6.190 | 6.060 |
| Cash Flow per Share 2 | -0.9100 | -1.780 | -0.7200 | - | - | -0.9100 | -0.5700 | - |
| Capex 1 | 792 | 580 | 772 | 394 | 828 | 586 | 329 | 373 |
| Capex / Sales | 102.13% | 36.4% | 19.19% | 27.1% | 55.14% | 31.92% | 10.36% | 10.3% |
| Announcement Date | 3/2/20 | 2/26/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.942
CNY
Average target price
22.5
CNY
Spread / Average Target
+126.33%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.75% | 3.18B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 1877 Stock
- Financials Shanghai Junshi Biosciences Co., Ltd.
